Invention Grant
- Patent Title: Protein kinase C inhibitors and methods of their use
-
Application No.: US16666108Application Date: 2019-10-28
-
Publication No.: US11059804B2Publication Date: 2021-07-13
- Inventor: Michael Joseph Luzzio , Julien Papillon , Michael Scott Visser
- Applicant: Novartis AG
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agency: Lathrop GPM LLP
- Agent Brian C. Trinque
- Main IPC: A61K31/497
- IPC: A61K31/497 ; C07D401/14 ; C07D413/14 ; A61P31/04 ; A61K31/506 ; A61P35/00 ; A61K45/06
Abstract:
PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.
Public/Granted literature
- US20200262814A1 PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE Public/Granted day:2020-08-20
Information query
IPC分类:
